EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAS pathway mutations in juvenile myelomonocytic leukemia



RAS pathway mutations in juvenile myelomonocytic leukemia



Acta Haematologica 119(4): 207-211



Juvenile myelomonocytic leukemia (JMML) is a rare blood cell malignancy occurring in very young children. Yet, just as has been proven in other rare diseases, the study of JMML has provided us great insights into aberrant and dysregulated signal transduction through the Ras pathway, with the ultimate development of malignancy. Further, JMML investigations have also revealed to us much about the genetic predisposition to cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333403

Download citation: RISBibTeXText

PMID: 18566538

DOI: 10.1159/000140632



Related references

Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia. Annals of Hematology 91(4): 511-517, 2012

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 98(1): 107-113, 2014

Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 115(10): 1969-1975, 2010

Clinical Characteristics of Children with Juvenile Myelomonocytic Leukemia and Germline or Somatic PTPN11 Mutations, Ras Mutations or Neurofibromatosis Type 1. Blood 100(11): Abstract No 3143, November 16, 2002

Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Pediatric Research 53(4 Part 2): 279A, April, 2003

Chronic low back pain and back muscle activity during functional tasks. Gait & Posture 61: 250-256, 2018

Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations. Blood 115(26): 5429-5431, 2010

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114(9): 1859-1863, 2009

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood 123(9): 1426-1427, 2014

Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Paediatric Drugs 14(3): 157-163, 2013

Analysis of activating FLT3 mutations in juvenile myelomonocytic leukemia. Blood 102(11): 662a, November 16, 2003

Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatric Blood & Cancer 44(2): 142-146, 2004

Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia. Zhongguo Dang Dai Er Ke Za Zhi 17(1): 1-5, 2015

Somatic mutations in PTPN11 in the Japanese patients with juvenile myelomonocytic leukemia. Blood 102(11): 366a-367a, November 16, 2003

Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Blood 120(7): 1485-1488, 2012